Entero Healthcare Solutions’ Board of Directors has approved the allotment of 3,420 equity shares under its Employee Stock Option Plan 2023. This follows the exercise of vested options by eligible employees. Additionally, the board approved the grant of 17,500 fresh employee stock options under the same plan. These decisions align with the company’s strategy to incentivize and retain its workforce through equity-based compensation.
Key Board Decisions on Employee Stock Options
Entero Healthcare Solutions Limited announced significant decisions made by its Board of Directors on June 11, 2026, pertaining to its employee stock option plans. The Board, acting on the recommendations of the Nomination and Remuneration Committee, has approved the allotment of 3,420 equity shares. These shares are being issued to eligible employees who have exercised their vested options under the Entero Employee Stock Option Plan 2023. Each share carries a par value of Rs. 10/-.
Grant of New Employee Stock Options
In a further move to bolster employee engagement and retention, the Board also noted the grant of 17,500 new Employee Stock Options (ESOPs). These fresh grants are also part of the existing Entero Employee Stock Option Plan 2023. The details of these grants, as required under SEBI regulations, have been furnished and are available in the accompanying annexures.
Details of Allotted Shares (Annexure-A)
The allotment of 3,420 equity shares resulted from the exercise of options at an exercise price of Rs. 804 per equity share. The total issued shares after this allotment now stand at 4,35,21,597, with a total issued share capital of Rs. 43,52,15,970. The shares issued are freely transferable and rank pari-passu with existing equity shares, with no lock-in period restrictions beyond applicable laws.
Details of Granted Options (Annexure-B)
The newly granted 17,500 options are also under the Entero Employee Stock Option Plan 2023 and are compliant with the SEBI (Share Based Employee Benefits) Regulations, 2021. These options have an exercise price of INR 804 per option. The vesting period for these options ranges from a minimum of 1 year to a maximum of 4 years from the grant date. The exercise period for vested options is 8 years from the vesting date.
Meeting Concluded
The Board Meeting commenced at 03:00 p.m. (IST) and concluded at 03:50 p.m. (IST) on June 11, 2026. The information regarding these board resolutions will be made available on the company’s website, www.enterohealthcare.com.
Source: BSE
